Patients undergoing chronic hemodialysis. Encounter for adequacy testing for hemodialysis
Conditions
Interventions
Intervention 1: Intervention group: During a four weeks’ period, the patients in intervention group take 500 mg hydroalcoholic extract of WC once a day and those in control group receive drug-like (ca
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 18 years of age and older Receive hemodialysis at least twice a week for about 3 months Negative history of taking drugs affecting inflammatory markers such as corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) in a recent month Absence of active infectious diseases, malignant and other obvious inflammatory diseases No history of taking tonics and anti-inflammatory drugs
Exclusion criteria
Exclusion criteria: Causes unpredictable drug side effects Patients who refused to cooperate and continue the study and received the drug for less than 4 weeks Development of active infectious diseases, cirrhosis and congestive heart failure and malignancy during the study and the need for kidney transplantation Malnutrition and cachexia (body mass index less than 18 kg / m2) Albumin less than 3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood urea nitrogen. Timepoint: 0-28 days. Method of measurement: Autoanalyzer.;Triglyceride. Timepoint: 0-28 days. Method of measurement: Autoanalyzer.;Cholestrol. Timepoint: 0-28 days. Method of measurement: Autoanalyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Protein carbonyl. Timepoint: 0-28 days. Method of measurement: colorimetric.;Interleukin 6. Timepoint: 0-28 days. Method of measurement: Sandwich Enzyme-Linked ImmunoSorbent Assay.;Tumor Necrosis Factor Alpha(TNF-a). Timepoint: 0-28 days. Method of measurement: Sandwich Enzyme-Linked ImmunoSorbent Assay.;Vitamin E. Timepoint: 0-28 days. Method of measurement: High-performance liquid.;Vitamin C. Timepoint: 0-28 days. Method of measurement: High-performance liquid. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Hossein Doustimotlagh
Yasouj University of Medical Sciences
Outcome results
None listed